More Clinuvel Pharmaceuticals Limited news
Clinuvel Pharmaceuticals LimitedASX: CUV

Media Release - CLINUVEL expands DNA Repair Program

Mar 23, 2021 at 11:14 PM EDT · Issued by Clinuvel Pharmaceuticals Limited

Filed with ASX · Mar 23, 2021 at 11:14 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/media-release-clinuvel-expands-dna-repair-program

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27↗

Clinuvel Pharmaceuticals Limited on 6ix

Story so far

  • Media Release - First patient dosed in SCENESSE DNA RepairSep 15, 2020
  • CLINUVEL progresses innovative DNA Repair ProgramSep 10, 2020

Earlier from Clinuvel Pharmaceuticals

  • Appendix 4D Half Yearly ReportFeb 24, 2021
  • CLINUVEL Strategic Update - ExtendedOct 29, 2020
  • Media Release - CLINUVEL to Trial Innovative Drug in StrokeOct 27, 2020
  • Australian TGA approves SCENESSEOct 27, 2020
  • Trading HaltOct 26, 2020

Later from Clinuvel Pharmaceuticals

  • Appendix 4C - quarterlyApr 29, 2021
  • Appendix 4E and Preliminary Financial ReportAug 26, 2021
  • CLINUVEL Delivers Record Revenues and ProfitAug 26, 2021
  • Response to ASX Price QueryNov 7, 2021
  • Appendix 4D Half Year ReportFeb 22, 2022
All Clinuvel Pharmaceuticals news releases↗

Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.

Follow Clinuvel Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer